Breckenridge Pharmaceutical Inc, the US subsidiary of Spain-based Towa International, announced on Monday the launch of Pomalidomide Capsules, a generic version of Pomalyst by Celgene (now Bristol Myers Squibb), within the oncology therapeutic category.
The product was developed in partnership with NATCO Pharma Limited of India.
Pomalidomide Capsules, a thalidomide analogue, are indicated for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy. It is also approved for AIDS-related Kaposi sarcoma after failure of highly active antiretroviral therapy, as well as for HIV-negative adult patients with Kaposi sarcoma.
The product is available in 1mg, 2mg, 3mg, and 4mg strengths and is distributed primarily through specialty pharmacies and clinics.
Pomalidomide Capsules are available only through a restricted programme called PS-Pomalidomide REMS.
INOVIO prices public offering of approximately USD75m
First patient dosed in Phase 1 trial of Transgene and BioInvent's BT-001 for rectal cancer
Elicera Therapeutics secures Chinese patent allowance for ELC-401
CHOSA Oncology signs US laboratory agreement for Platin-DRP commercialisation
BeOne Medicines wins FDA Priority Review for BRUKINSA combination in first-line mantle cell lymphoma
United Therapeutics eliminates Pfizer royalty obligations on ralinepag for USD525m
Pentixapharm advances preparationsfor Phase 3 PANDA study
ABIONYX Pharma partners with Lille University Hospital to explore CER-001 for severe burn patients
CStone and Kimia Therapeutics collaborate to advance oncology drug candidate
Merck launches Phase 3 trial of Ohtuvayre for COPD exacerbation prevention
Vivesto secures US orphan drug designation for Cantrixil in acute myeloid leukemia
Lytix Biopharma's ruxotemitide combination meets primary endpoint in Phase II melanoma trial